An In Vitro Kinase Assay to Assess Rac1 Phosphorylation by ERK

Author(s):  
Daniel Brandwein ◽  
Junfeng Tong ◽  
Laiji Li ◽  
Barbara Ballermann ◽  
Zhixiang Wang
2008 ◽  
Vol 411 (1) ◽  
pp. 27-32 ◽  
Author(s):  
Masato Iida ◽  
Masao Matsuda ◽  
Hideya Komatani

The Plk (polo-like kinase) family is involved in cell-cycle machinery. Despite the possible overlapping involvement of Plk1 and Plk3 in cell-cycle distribution, the precise role of each Plk might be different. To investigate mechanisms that may differentiate their physiological roles, we compared the substrate specificities of Plk1 and Plk3 using synthetic peptides. Among these substrate peptides, topoisomerase IIα EKT1342DDE-containing synthetic peptide was strongly phosphorylated by Plk3 but not by Plk1. By modulating the topoisomerase IIα peptide, we identified residues at positions +1, +2 and +4 as determinants of differential substrate recognition between Plk1 and Plk3. Acidic residues at positions +2 and +4 appear to be a positive determinant for Plk3 but not Plk1. Variation at position +1 appears to be tolerated by Plk3, while a hydrophobic residue at +1 is critical for Plk1 activity. The direct phosphorylation of Thr1342 of topoisomerase IIα by Plk3 was demonstrated with an in vitro kinase assay, and overexpression of Plk3 induced the phosphorylation of Thr1342 in cellular topoisomerase IIα. Furthermore, the physical interaction between Plk3 and topoisomerase IIα was also demonstrated in cells in addition to phosphorylation. These data suggest that topoisomerase IIα is a novel physiological substrate for Plk3 and that Plk1 and Plk3 play different roles in cell-cycle regulation.


Oncology ◽  
2006 ◽  
Vol 71 (3-4) ◽  
pp. 297-305 ◽  
Author(s):  
Wei Mai ◽  
Katsuyoshi Miyashita ◽  
Abbas Shakoori ◽  
Bin Zhang ◽  
Zhi Wei Yu ◽  
...  

2005 ◽  
Vol 10 (1) ◽  
pp. 36-45 ◽  
Author(s):  
Helmut Mett ◽  
Kerstin Hölscher ◽  
Heidrun Degen ◽  
Christina Esdar ◽  
Birgit Felden De Neumann ◽  
...  

The human cytomegalovirus (HCMV) protein kinase pUL97 represents an important determinant for viral replication and thus is a promising target for the treatment of HCMV. The authors screened a compound library of nearly 5000 entities based on known kinase inhibitors in 2 distinct ways. A radioactive in vitro kinase assay was performed with recombinant pUL97, purified from baculovirus-infected insect cells, on myelin basic protein-coated FlashPlates. About 20% of all compounds tested inhibited pUL97 kinase activity by more than 50% at a concentration of 10 μM. These hits belonged to various structural classes. To elucidate their potential to inhibit pUL97 in a cellular context, all compounds of the library were also tested in a cell-based activity assay. For this reason, a HEK293 cell line was established that ectopically expressed pUL97. When these cells were incubated with ganciclovir (GCV), pUL97 phosphorylated GCV to its monophosphate, which subsequently became phosphorylated to cytotoxic metabolites by cellular enzymes. Thereby, pUL97 converted cells into a GCV-sensitive phenotype. Inhibition of the pUL97 kinase activity resulted in protection of the cells against the cytotoxic effects of GCV. In total, 199 compounds of the library were cellular active at nontoxic concentrations, and 93 of them inhibited pUL97 in the in vitro kinase assay. Among these, promising inhibitors of HCMV replication were identified. The 2-fold screening system described here should facilitate the development of pUL97 inhibitors into potent drug candidates. ( Journal of Biomolecular Screening 2005:36-45)


2019 ◽  
Vol 21 (Supplement_6) ◽  
pp. vi69-vi69
Author(s):  
Subhas Mukherjee ◽  
Gary Schiltz ◽  
Matt Clutter ◽  
Rama Mishra ◽  
Cheryl Olson ◽  
...  

Abstract The survival advantage of glioma stem cells (GSCs) represents a critical mechanism for growth, therapy resistance and recurrence in glioblastoma. So far, targeting GSCs has not been highly specific, since these cells co-opt the normal developmental signaling pathways. We have demonstrated that the activated CDK5-CREB1 signaling axis regulates GSC self-renewal and also promotes radiation-resistance. Thus targeting CDK5 signaling is highly rational, yet there are challenges. Most of the available CDK5 inhibitors also target other CDKs non-specifically. In collaboration with The Center for Molecular Evolution and Drug Discovery, we are developing novel CDK5 inhibitors that are highly potent and specific. METHODOLOGY: The CKD5-p25 crystal structure (pdb code 1UNL) was used to conduct a virtual high throughput screen (vHTS). A library of 10 million commercially available compounds which had been filtered to ensure they possessed good drug-like properties was screened against the crystal structure. The top 33 compounds based on their predicted target binding, synthetic feasibility and availability were tested in an in vitro kinase assay to measure CDK5 inhibition. RESULTS: Of the 33 potential hit, 11 compounds showed a CDK5 inhibition of < 50 µM. These 11 hits represent 4 distinct chemical scaffolds. Two of them have IC50 < 1 µM, with one compound having an IC50 < 0.4 µM. The vHTS and subsequent in vitro testing have therefore confirmed the identification of several new series of potent CDK5 hit compounds. We are now characterizing the kinase selectivity of our different hit series and evaluating their activity in cell-based assays. This will help focus efforts on the most promising 1–2 scaffolds for further medicinal chemistry optimization to improve the compounds’ potency, selectivity and brain penetration. Ultimately, our optimized compounds will be tested in GBM models to demonstrate their effectiveness in inhibiting CDK5 as a new approach for treating GBM.


1997 ◽  
Vol 137 (1) ◽  
pp. 247-258 ◽  
Author(s):  
Yousef Abu-Amer ◽  
F. Patrick Ross ◽  
Paul Schlesinger ◽  
M. Mehrdad Tondravi ◽  
Steven L. Teitelbaum

The osteoclast is distinguished from other macrophage polykaryons by its polarization, a feature induced by substrate recognition. The most striking component of the polarized osteoclast is its ruffled membrane, probably reflecting insertion of intracellular vesicles into the bone apposed plasmalemma. The failure of osteoclasts in c-src−/− osteopetrotic mice to form ruffled membranes indicates pp60c-src (c-src) is essential to osteoclast polarization. Interestingly, c-src itself is a vesicular protein that targets the ruffled membrane. This being the case, we hypothesized that matrix recognition by osteoclasts, and their precursors, induces c-src to associate with microtubules that traffic proteins to the cell surface. We find abundant c-src associates with tubulin immunoprecipitated from avian marrow macrophages (osteoclast precursors) maintained in the adherent, but not nonadherent, state. Since the two proteins colocalize only within adherent avian osteoclast-like cells examined by double antibody immunoconfocal microscopy, c-src/tubulin association reflects an authentic intracellular event. C-src/tubulin association is evident within 90 min of cell-substrate recognition, and the event does not reflect increased expression of either protein. In vitro kinase assay demonstrates tubulin-associated c-src is enzymatically active, phosphorylating itself as well as exogenous substrate. The increase in microtubule-associated kinase activity attending adhesion mirrors tubulin-bound c-src and does not reflect enhanced specific activity. The fact that microtubule-dissociating drugs, as well as cold, prevent adherence-induced c-src/tubulin association indicates the protooncogene complexes primarily, if not exclusively, with polymerized tubulin. Association of the two proteins does not depend upon protein tyrosine phosphorylation and is substrate specific, as it is induced by vitronectin and fibronectin but not type 1 collagen. Finally, consistent with cotransport of c-src and the osteoclast vacuolar proton pump to the polarized plasmalemma, the H+-ATPase decorates microtubules in a manner similar to the protooncogene, specifically coimmunoprecipitates with c-src from the osteoclast light Golgi membrane fraction, and is present, with c-src, in preparations enriched with acidifying vesicles reconstituted from the osteoclast ruffled membrane.


Blood ◽  
1997 ◽  
Vol 90 (3) ◽  
pp. 929-934 ◽  
Author(s):  
Yuka Nagata ◽  
Tetsuo Moriguchi ◽  
Eisuke Nishida ◽  
Kazuo Todokoro

Activation of p38 MAP kinase (p38) as well as JNK/SAPK has been described as being induced by a variety of environmental stresses such as osmotic shock, ultraviolet radiation, and heat shock, or the proinflammatory cytokines tumor necrosis factor-α and interleukin-1 (IL-3). We found that the hematopoietic cytokines erythropoietin (Epo) and IL-3, which regulate growth and differentiation of erythroids and hematopoietic progenitors, respectively, also activate a p38 cascade. Immunoblot analyses and in vitro kinase assay clearly showed that Epo and IL-3 rapidly and transiently phosphorylated and activated p38 in Epo– or IL-3–dependent mouse hematopoietic progenitor cells. p38 can generally be activated by the upstream kinase MKK3 or MKK6. However, in vitro kinase assays in the immunoprecipitates with anti-MKK6 antibody and anti-phosphorylated MKK3/MKK6 antibody showed that activation of neither MKK3 nor MKK6 was detected after Epo or IL-3 stimulation, while osmotic shock clearly induced activation of both MKK3/MKK6 and p38. Together with previous observations, these results suggest that both p38 and JNK cascades play an important role not only in stress and proinflammatory cytokine responses but also in hematopoietic cytokine actions.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2566-2566 ◽  
Author(s):  
Michael B. Lilly ◽  
Sheldon Holder ◽  
Marina Zemskova ◽  
Jonathan Neidigh

Abstract The pim family of kinases are small cytoplasmic serine/threonine kinases implicated in the development of leukemias, lymphomas, and prostate cancer. Expression of pim-1 and pim-2 is induced by several oncogenes and growth factors. These kinases confer a survival phenotype through modulation of the expression or activity of various bcl-2 family members. To identify prototype small molecule inhibitors of pim-1 we have undertaken a series of experimental and computational studies. Central to our efforts has been the development of a homology model of the PIM-1 protein, using death-associated kinase as a template. After a series of computational refinements using the CFF forcefield, we then further modified our model through experimental approaches. The members of the pim family appear to have a unique, conserved structure to the hinge region, based on its length and the presence of two invariant prolines. This observation suggested that ATP-pocket binding compounds could be identified that would have selectivity for pim-1. We used a liquid phase, ELISA-based in vitro kinase assay to measure IC50 values for a set of 14 flavonoids, a family of known kinase inhibitors. Calculated binding energies for the test flavonoids were then compared with measured IC50 values, and the model giving the highest correlations was then used for further studies. A set of 25 additional flavonoids was then examined for binding energy to the homology model. Our studies predicted that the flavonoids quercetagetin and gossypetin could be potential pim-1 inhibitors. This hypothesis was then tested by in vitro kinase assay. Indeed these two flavonoids were found to be active pim-1 inhibitors with high-nanomolar potency. Quercetagetin was found to be competitive with ATP in the kinase assay. Furthermore the two flavonoids were seen to have a degree of selectivity for pim-1 kinase, compared with related serine-threonine kinases and a tyrosine kinase. IC50 (micromolar) of flavonoids against PIM-1 and other kinases Inhibitor PIM-1 PIM-2 cAMP-dep. kinase c-ABL quercetagetin 0.33 4.0 21 >200 gossypetin 0.430 7.1 250 >200 quercetin 2.0 ND ND 5.7 In contrast the potency and pim-1-selectivity of the related flavonoid quercetin (a promiscuous inhibitor of kinases) was much inferior. SAR analysis of the flavonoid set showed that pim-1 selectivity depended on the presence of three hydrogen bond donors on the flavonoid A ring. Quercetagetin has been tested for biologic effects on factor-dependent FDCP1 cells transfected with a cDNA for human pim-1. These test cells show prolonged, pim-1-dependent survival after removal of IL-3 from the growth medium. This phenotype was completely abolished by treatment with quercetagetin (IC50 = 3-5micromolar final concentration). Flavonoids such as quercetagetin and gossypetin may serve as guides for the development of small molecule inhibitors specific for pim family kinases. Such reagents will be useful for determining the role of constitutive pim-1 expression in the development of leukemias and lymphomas.


Blood ◽  
2005 ◽  
Vol 105 (10) ◽  
pp. 3918-3924 ◽  
Author(s):  
Carol A. Dangelmaier ◽  
Patricia G. Quinter ◽  
Jianguo Jin ◽  
Alexander Y. Tsygankov ◽  
Satya P. Kunapuli ◽  
...  

AbstractSpleen tyrosine kinase (Syk) activation is a key intermediate step in the activation of platelets by the physiologic agonist collagen. We have found that Syk is rapidly ubiquitinated upon activation of platelets by collagen, collagen-related peptide (CRP), and convulxin. The Src family kinase inhibitors prevented Syk phosphorylation and its ubiquitination, indicating that the process is downstream of Src kinases. The ubiquitination of Syk did not cause degradation of the protein as evidenced by the lack of effect of proteasomal and lysosomal inhibitors. We separated ubiquitinated Syk from its nonubiquitinated counterpart and used an in vitro kinase assay to compare their activities. We found that the ubiquitinated Syk appeared to be about 5-fold more active. Using a phosphospecific antibody to Syk (Tyr525/Tyr526) that measures activated Syk, we found that most (60%-75%) of the active Syk is in the ubiquitinated fraction. This result explains the apparent high specific activity of ubiquitinated Syk. In c-Cbl–deficient mice, Syk is not ubiquitinated, implicating c-Cbl as the E3 ligase involved in Syk ubiquitination. Furthermore, Syk is not dephosphorylated in these mice. We propose that c-Cbl plays a regulatory role in glycoprotein VI (GPVI)/Fc receptor γ (FcRγ)-chain–dependent platelet activation through its interaction with Syk.


Biomolecules ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 546 ◽  
Author(s):  
Yo Han Hong ◽  
Ji Hye Kim ◽  
Jae Youl Cho

(1) Background: Ranunculus bulumei is a flowering plant that belongs to the Ranunculus species. Several Ranunculus species, such as R. aquatilis and R. muricatus, have traditionally been used to treat fever and rheumatism throughout Asia, suggesting that plants belonging to the Ranunculus species may have anti-inflammatory effects. To our knowledge, the pharmacological activity of R. bulumei has not been reported. Therefore, in this study, we aim to assess the anti-inflammatory activity of a methanol extract that was derived from R. bulumei (Rb-ME) in macrophage-mediated inflammatory responses and to identify the molecular mechanism that underlies any anti-inflammatory action. (2) Methods: The anti-inflammatory efficacy of Rb-ME was evaluated while using in vitro and in vivo experiments. The RAW264.7 cells and peritoneal macrophages were stimulated by lipopolysaccharide (LPS). In addition, LPS-induced peritonitis and HCl/EtOH-triggered gastritis models were produced. A nitric oxide (NO) assay, real-time PCR, luciferase reporter gene assay, western blot analysis, plasmid overexpression strategy, and in vitro kinase assay were used to determine the molecular mechanisms and target molecules of Rb-ME. The phytochemical active ingredients of Rb-ME were also identified by high performance liquid chromatograph (HPLC). (3) Results: Rb-ME reduced the production of NO and mRNA expression of iNOS, COX-2, IL-1β, and IL-6 without cytotoxicity. The protein secretion of TNF-α and IL-6 was also decreased by Rb-ME. HPLC analysis indicates that quercetin, luteolin, and kaempferol are the main active ingredients in the anti-inflammatory efficacy of Rb-ME. Rb-ME also blocked MyD88-induced NF-κB promoter activity and nuclear translocation of NF-κB subunits (p65 and p50). Moreover, Rb-ME reduced the phosphorylation of IκBα, Akt, p85, Src, and Syk, which are NF-κB upstream signaling molecules in LPS-activated RAW264.7 cells. According to the in vitro kinase assay, Rb-ME directly inhibits Syk kinase activity. The oral administration of Rb-ME alleviated inflammatory responses and the levels of p-IκBα in mice with LPS-induced peritonitis and HCl/EtOH-induced gastritis. (4) Conclusions Rb-ME has anti-inflammatory capacity by suppressing NF-κB signaling and it has been found to target Src and Syk in the NF-κB pathway. Based on this efficacy, Rb-ME could be developed as an anti-inflammatory herbal medicine.


Sign in / Sign up

Export Citation Format

Share Document